Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: BI-1569912
BI 1569912 is a small-molecule, orally administered negative allosteric modulator of GluN2B-containing NMDA receptors. Clinical development has included Phase I pharmacokinetic and safety studies in healthy participants and Phase Ib/Phase II studies in major depressive disorder. It has not been approved for commercial therapeutic use.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence-backed clinical research regimens include single oral doses of 2.5 mg, 5 mg, 10 mg and 20 mg in healthy-participant Phase I studies; 20 mg once daily for 14 days in one multiple-dose study; and 5 mg, 10 mg or 20 mg once daily for 6 weeks in Phase II dose-finding studies. A human absorption, distribution, metabolism and excretion study used a single oral radiolabeled dose with a concomitant intravenous microdose for absolute-bioavailability assessment. These are historical study regimens, not treatment or self-administration recommendations. BI 1569912 remains investigational and no approved therapeutic labeling, standardized storage specification, chemical structure, molecular formula, CAS number, solubility specification or commercial reference-size standard was reliably identified in the authoritative sources reviewed.
Supplementary research context only. Not medical advice or a treatment recommendation.
Development code: BI 1569912; BI trial numbers include 1447-0001, 1447-0002, 1447-0004, 1447-0005, 1447-0010 and 1447-0012; ClinicalTrials.gov identifiers include NCT04445090, NCT04978506, NCT04958252, NCT04937829, NCT06280235, NCT06367153, NCT06520553 and NCT06558344; PMID 42684025; PMID 40810366; DOI 10.1177/02698811261481073; DOI 10.1002/cpt.70018.
Clinical protocols describe BI 1569912 as a potent NR2B-containing NMDA receptor negative allosteric modulator with an in-vitro EC50 of 16 nM. Human Phase I studies reported rapid oral absorption, approximately dose-proportional exposure, median time to maximum plasma concentration of about 0.5 hours under fasted conditions, and a short terminal half-life of approximately 4 hours. Food reduced maximum plasma concentration and delayed time to maximum concentration without materially changing exposure measured by area under the curve. Unchanged urinary excretion was negligible or very low.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention BI 1569912 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.